Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$3.95
-1.5%
$3.48
$2.00
$5.00
$18.84M2.25826,180 shs35,494 shs
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$3.00
$2.85
$1.47
$16.87
$73.29M2.83200,866 shs25,767 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.81
+1.1%
$1.86
$0.98
$3.44
$73.00M0.2435,014 shs29,222 shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.86
+0.2%
$0.88
$0.52
$4.60
$72.48M1.611.13 million shs546,633 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
+3.62%+16.23%+11.08%+27.71%+55.73%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+3.45%+2.74%-2.91%+67.60%-79.81%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-0.28%0.00%-5.79%-20.44%-24.23%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
+1.35%-5.46%-13.09%+4.39%-75.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$3.95
-1.5%
$3.48
$2.00
$5.00
$18.84M2.25826,180 shs35,494 shs
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$3.00
$2.85
$1.47
$16.87
$73.29M2.83200,866 shs25,767 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.81
+1.1%
$1.86
$0.98
$3.44
$73.00M0.2435,014 shs29,222 shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.86
+0.2%
$0.88
$0.52
$4.60
$72.48M1.611.13 million shs546,633 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
+3.62%+16.23%+11.08%+27.71%+55.73%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+3.45%+2.74%-2.91%+67.60%-79.81%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-0.28%0.00%-5.79%-20.44%-24.23%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
+1.35%-5.46%-13.09%+4.39%-75.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ainos, Inc. stock logo
AIMD
Ainos
1.00
SellN/AN/A
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.60
Moderate Buy$17.00466.67% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.00
Hold$4.47422.42% Upside

Current Analyst Ratings Breakdown

Latest AIMD, ARTV, STRO, and BYSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Ainos, Inc. stock logo
AIMD
Ainos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/12/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$4.00 ➝ $3.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ainos, Inc. stock logo
AIMD
Ainos
$20K942.08N/AN/A$5.51 per share0.72
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K293.16N/AN/A$7.68 per share0.39
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M41.71N/AN/A($0.37) per share-4.89
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$62.04M1.17N/AN/A$0.54 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$4.99N/AN/AN/A-108.25%-56.94%11/5/2025 (Estimated)
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/A11/12/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$227.46M-$2.53N/AN/AN/A-201.32%-852.70%-58.67%11/12/2025 (Estimated)

Latest AIMD, ARTV, STRO, and BYSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$0.99N/A-$0.99N/AN/A
8/13/2025Q2 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.04N/A-$0.04N/AN/A
8/7/2025Q2 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.39-$0.14+$0.25-$0.14$14.55 million$63.74 million
8/6/2025Q2 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.84-$0.87-$0.03-$0.87N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ainos, Inc. stock logo
AIMD
Ainos
0.96
2.88
2.61
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.84
13.84
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.19
2.19
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
3.12
3.12

Institutional Ownership

CompanyInstitutional Ownership
Ainos, Inc. stock logo
AIMD
Ainos
N/A
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%

Insider Ownership

CompanyInsider Ownership
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ainos, Inc. stock logo
AIMD
Ainos
404.77 million4.28 millionNot Optionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.43 million19.20 millionN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.33 million28.51 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.77 million81.72 millionOptionable

Recent News About These Companies

Sutro Biopharma trims workforce again to extend cash runway
Sutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street Zen
Sutro Biopharma (STRO) Gets a Buy from Truist Financial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ainos stock logo

Ainos NASDAQ:AIMD

$3.95 -0.06 (-1.50%)
As of 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$3.00 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.01 +0.01 (+0.33%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$1.81 +0.02 (+1.12%)
Closing price 03:59 PM Eastern
Extended Trading
$1.84 +0.03 (+1.66%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.86 +0.00 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.00 (+0.35%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.